Top

Journal of Inherited Metabolic Disease

Published in:

01-11-2012 | Original Article

An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia

Authors: Thomas Opladen, Georg F. Hoffmann, Nenad Blau

Published in: Journal of Inherited Metabolic Disease | Issue 6/2012

Abstract

Objectives

The present study summarizes clinical and biochemical findings, current treatment strategies and follow-up in patients with tetrahydrobiopterin (BH₄) deficiencies.

Methods

We analyzed the clinical, biochemical and treatment data of 626 patients with BH₄ deficiencies [355 with 6-pyruvoyl-tetrahydropterin synthase (PTPS), 217 with dihydropteridine reductase (DHPR), 31 with autosomal recessive GTP cyclohydrolase I (GTPCH), and 23 with pterin-4a-carbinolamine dehydratase (PCD) deficiencies] from the BIODEF Database. Patients with autosomal dominant GTPCH and SR deficiencies will not be discussed in detail.

Results

Up to 57 % of neonates with BH₄ deficiencies are already clinically symptomatic. During infancy and childhood, the predominant symptoms are muscular hypotonia, mental retardation and age-dependent movement disorders, including dystonia. The laboratory diagnosis of BH₄ deficiency is based on a positive newborn screening (NBS) for phenylketonuria (PKU), characteristic profiles of urinary or dried blood spot pterins (biopterin, neopterin, and primapterin), and the measurement of DHPR activity in blood. Some patients with autosomal recessive GTPCH deficiency and all with sepiapterin reductase deficiency may be diagnosed late due to normal blood phenylalanine in NBS. L-dopa, 5-hydroxytryptophan, and BH₄ are supplemented in PTPS and GTPCH-deficient patients, whereas L-dopa, 5-hydroxytryptophan, folinic acid and diet are used in DHPR-deficient patients. Medication doses vary widely among patients, and our understanding of the effects of dopamine agonists and monoamine catabolism inhibitors are limited.

Conclusions

BH₄ deficiencies are a group of treatable pediatric neurotransmitter disorders that are characterized by motor dysfunction, mental retardation, impaired muscle tone, movement disorders and epileptic seizures. Although the outcomes of BH₄ deficiencies are highly variable, early diagnosis and treatment result in improved outcomes.

al Aqeel A, Ozand PT, Gascon G et al (1991) Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Neurology 41:730–737PubMedCrossRef

Blau N, Burgard P (2006) Disorders of Phenylalanine and Tetrahydrobiopterin Metabolism. In: Blau N, Hoffmann GF, Leonard J, Clarke JTR (eds) Physician’s Guide to the Treatment and Follow-up of Metabolic Diseases. Springer, Berlin, pp 25–34CrossRef

Blau N, Barnes I, Dhondt JL (1996) International database of tetrahydrobiopterin deficiencies. J Inherit Metab Dis 19:8–14PubMedCrossRef

Blau N, Thöny B, Cotton RGH, Hyland K (2001) Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B (eds) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York, pp 1725–1776

Blau N, Duran M, Blaskovics M, Gibson KM (2003) Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Blau N, Bonafe L, Blaskovics M (eds) Physician's Guide to Laboratory Diagnosis of Metabolic Diseases. Springer, Berlin, pp 89–106CrossRef

Blau N, Duran M, Gibson KM (2008) Laboratory guide to the methods in biochemical genetics. Springer, BerlinCrossRef

Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427PubMedCrossRef

Bonafe L, Thöny B, Leimbacher W, Kierat L, Blau N (2001) Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 47:477–485PubMed

Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N (2001) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 69:269–277PubMedCrossRef

Concolino D, Muzzi G, Rapsomaniki M, Moricca MT, Pascale MG, Strisciuglio P (2008) Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. J Inherit Metab Dis Dec 31:S193–S197CrossRef

Crabtree MJ, Tatham AL, Al-Wakeel Y et al (2009) Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 284:1136–1144PubMedCrossRef

Friedman J, Roze E, Abdenur JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520–530.

Fukushima T, Nixon JC (1980) Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 102:176–188PubMedCrossRef

Gasnier B (2000) The loading of neurotransmitters into synaptic vesicles. Biochimie 82:327–337PubMedCrossRef

Herlenius E, Lagercrantz H (2001) Neurotransmitters and neuromodulators during early human development. Early Hum Dev 65:21–37PubMedCrossRef

Irons M, Levy HL, O'Flynn ME et al (1987) Folinic acid therapy in treatment of dihydropteridine reductase deficiency. J Pediatr 110:61–67PubMedCrossRef

Jäggi L, Zurfluh MR, Schuler A et al (2008) Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 93:295–305PubMedCrossRef

Longo N (2009) Disorders of biopterin metabolism. J Inherit Metab Dis 32:333–342PubMedCrossRef

Niu DM (2011) Disorders of BH4 metabolism and the treatment of patients with 6-pyruvoyl-tetrahydropterin synthase deficiency in Taiwan. Brain Dev 33:847–855PubMedCrossRef

Opladen T, Abu Seda B, Rassi A, Thöny B, Hoffmann GF, Blau N (2011a) Diagnosis of tetrahydrobiopterin deficiency using filter paper blood spots: further development of the method and 5 years experience. J Inherit Metab Dis Jun 34:819–826CrossRef

Opladen T, Hoffmann G, Hörster F et al (2011b) Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 26:157–161PubMedCrossRef

Ponzone A, Blau N, Guardamagna O, Ferrero GB, Dianzani I, Endres W (1990) Progression of 6-pyruvoyl-tetrahydropterin synthase deficiency from a peripheral into a central phenotype. J Inherit Metab Dis 13:298–300PubMedCrossRef

Ponzone A, Guardamagna O, Ferraris S, Ferrero GB, Dianzani I, Cotton RGH (1991) Tetrahydrobiopterin loading test in hyperphenylalaninemia. Pediatr Res 30:435–438PubMedCrossRef

Ponzone A, Spada M, Ferraris S, Dianzani I, De Sanctis L (2004) Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 24:127–150PubMedCrossRef

Porta F, Mussa A, Concolino D, Spada M, Ponzone A (2009) Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 73:633–637PubMedCrossRef

Smith I, Clayton BE, Wolff OH (1975) New variant of phenylketonuria with progressive neurological illness unresponsive to phenylalanine restriction. Lancet 1:1108–1111PubMedCrossRef

Smith I, Hyland K, Kendall B (1985) Clinical role of pteridine therapy in tetrahydrobiopterin deficiency. J Inherit Metab Dis 8:39–45PubMedCrossRef

Thöny B, Blau N (2006) Mutations in the BH4-metabolizing genes GTP cyclohydroalse I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase genes. Hum Mutat 27:870–878PubMedCrossRef

Wang L, Yu WM, He C et al (2006) Long-term outcome and neuroradiological findings of 31 patients with 6-pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis 29:127–134PubMedCrossRef

Werner ER, Blau N, Thöny B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438:397–414PubMed

Woody R, Brewster M, Glasier C (1989) Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy. Neurology 39:673–675PubMedCrossRef

Title: An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia
Authors: Thomas Opladen
Georg F. Hoffmann
Nenad Blau
Publication date: 01-11-2012
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 6/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-012-9506-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia

Cultural aspects in the management of inborn errors of metabolism

Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients

Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts

Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria

Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials